The TAME trial was supposed to answer whether metformin can delay aging in humans. As of 2026, it is still running with no efficacy results — but its regulatory legacy is already reshaping the field.
The TAME trial is the most consequential aging study currently running in humans — not because it will definitively prove metformin extends lifespan, but because it created the regulatory framework for treating aging as a clinical target. As of early 2026, enrollment is ongoing. No efficacy results have been published.
This is a focused status update on where the trial stands. For metformin's mechanisms and the broader scientific case for and against it as an anti-aging drug, see our Metformin for Longevity review.
TAME — Targeting Aging with Metformin — is a randomized, double-blind, placebo-controlled trial testing whether metformin can delay the onset of age-related diseases in non-diabetic adults.
| Principal Investigator | Nir Barzilai, M.D., Albert Einstein College of Medicine |
| Coordinating Center | Wake Forest University School of Medicine |